Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-05-18
2010-12-14
Shafer, Shulamith H. (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S061000, C514S042000, C514S012200, C530S397000, C530S402000, C530S380000, C530S350000
Reexamination Certificate
active
07851438
ABSTRACT:
Methods and materials are provided for the production of compositions of erythropoietin protein, wherein said compositions comprise a pre-selected N-linked glycosylation pattern as the predominant N-glycoform.
REFERENCES:
patent: 4835260 (1989-05-01), Shoemaker
patent: 5641663 (1997-06-01), Garvin et al.
patent: 6077939 (2000-06-01), Wei et al.
patent: 7029872 (2006-04-01), Gerngross
patent: 7326681 (2008-02-01), Gergross
patent: 7332299 (2008-02-01), Hamilton
patent: 7405198 (2008-07-01), DeFrees et al.
patent: 7449308 (2008-11-01), Gerngross et al.
patent: 2004/0018590 (2004-01-01), Gerngross et al.
patent: 2007/0037248 (2007-02-01), Bobrowicz et al.
patent: 0154316 (1985-03-01), None
patent: 0315456 (1988-11-01), None
patent: 0401384 (1989-12-01), None
patent: 9402611 (1994-02-01), None
patent: 9424160 (1994-10-01), None
patent: 9425055 (1994-11-01), None
patent: 9505465 (1995-02-01), None
patent: 9605309 (1996-02-01), None
patent: 9611953 (1996-04-01), None
patent: 0032772 (2000-06-01), None
patent: 2004033651 (2004-04-01), None
patent: 2004074458 (2004-09-01), None
Llop et al 2008. Anal Biochem 383:243-254.
Takeuchi et al. 1988. J. Biol. Chem. 263:3657-3663.
Hamilton et al. 2006. Science 313:1441-1443.
Brooks. 2004. 28:241-255.
Bernaudin et al., “Potential Role for Erythropoietin in Focal Permanent Cerebral Ischemia in Mice”, Journal of Cerebral Blood Flow & Metabolism, vol. 19, pp. 643-651 (1999).
Briggs et al., “Hepatic clearance of intact and desialylated erythropoietin”, Americal Journal of Physiology, vol. 227, No. 6, pp. 1385-1388 (1974).
Broudy et al., “Recombinant Human Erythropoietin: Purification and Analysis of Carbohydrate Linkage”, Archives of Biochemistry and Biophysics, vol. 265, No., 2, pp. 329-336, (1988).
Caldas et al., “Design and systhesis of germline-based hemi-humanized single-chain Fv against the CD18 surface antigen”, Protein Engineering, vol. 13, No. 5, pp. 353-360, (2000).
Celik et al., “Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury”, PNAS, vol. 99, No. 4, pp. 2258-2263 (2002).
Danna et al., “Erythoropoietin Therapy for the Anemia Associated with AIDS and AIDS Therapy and Cancer”, ed. Erythropoietin in Clinical Applications—An Internationl Perspective, N.Y., NY, Marcel Dekker, Inc. pp. 301-324 (1990).
Deininger et al., “Galectin-3 Labeling Correlates Positively in Tumor Cells and Negatively in Endothelial Cells with Malignancy and Poor Progonosis in Oligodendroglioma Patients”, Anticancer Research 22, pp. 1585-1592 (2002).
Dordal et al., The Role of Carbohydrate in Erythropoietin Action:, Endocrinology, vol. 116, No. 6, pp. 2293-2299 (1985).
Dube et al., “Glycosylation at Specific Sites of Erythropoietin Is Essential for Biosynthesis, Secretion, and Biological Function”, The Journal of Biological Chemistry, vol. 263, No. 33, pp. 17516-17521 (1988).
Egrie et al., “Characterization and Biological Effects of Recombinant Human Erythropoietin”, Immunobiol, vol. 172, pp. 213-224 (1986).
Francis et al., “PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimisation of coupling techniques”, Internationl Journal of Hematology 68, pp. 1-18 (1998).
Fukuda et al., “Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates”, Blood, vol. 73, No. 1, pp. 84-89 (1989).
Ashwell G. and Kawasaki T., “A Protein from Mammalian Liver that Specifically Binds Galactose-Terminated Glycoproteins”, Methods in Enzymology 50, Complex Carbohydrates, Mammalian-Binding Protein, pp. 287-288 (1978).
Goldwasser et al., “On the Mechanism of Erythropoietin-induced Differentiation”, The Journal of Biological Chemistry, vol. 249, No. 13., p. 4202-4206 (1974).
Hamilton, et al, “Humanization of Yeast to Produce Complex Terminally Sialylated Glycoproteins”, Science, vol. 313, pp. 1441-1443 (2006).
Higuchi et al., “Role of Sugar Chains in the Expression of the Biological Activity of Human Erythropoietin”, The Journal of Biological Chemistry, vol. 267, No. 11, pp. 7703-7709 (1992).
Junk et al., “Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury”, PNAS, vol. 99, No. 16, pp. 10659-10664 (2002).
Lai et al., “Structural Characterization of Human Erythropoietin”, The Journal of Biological Chemistry, vol. 261, No. 7, pp. 3116-3121 (1986).
Lee-Huang et al., “Cloning and expression of human erythropoietin cDNA inEscherichia coli”, Proc. Natl, Acad. Sci. USA, vol. 81, pp. 2708-2712 (1984).
Marks et al., “Human Antibodies from V-gene Libraries Displayed on Phage”, J. Mol. Biol. 222, pp. 581-597 (1991).
Morell et al., “Physical and Chemical Studies on Ceruloplasmin”, The Journal of Biological Chemistry, vol. 243, No. 1, pp. 155-159 (1968).
Restelli et al., “The Effect of Dissolved Oxygen on the Production and the Glycosylation Profile of Recombinant Human Erythropoietin Produced From CHO Cells”, Biotechnology and Bioengineering, vol. 94, No. 3, pp. 481-494 (2006).
Sasaki et al., “Carbohydrate Structure of Erythropoietin Expressed in Chinese Hamster Ovary Cells by a Human Erythropoietin cDNA”, The Journal of Biological Chemistry, vol. 262, No. 25, pp. 12059-12076, (1987).
Yamaguchi et al, “Effects of Site-directed Removal of N-Glycosylation Sites in Human Erythropoietin on Its Production and Biological Properties”, The Journal of Biological Chemistry, vol. 266, No. 30, pp. 20434-20439 (1991).
Lowy et al, “Inactivation of Erythropoietin by Neuraminidase and by Mild Substitution Reactions”, Nature 185, pp. 102-103 (1960).
Hamilton et al, “Production of Complex Human Glycoproteins in Yeast”, Science, vol. 301, pp. 1244-1246 (2003).
Takeuchi et al., “Role of Sugar Chains in the in Vigtro Biological Activity of Human Erythropoietin Produced in Recombinant Chinese Hamster Ovary Cells”, The Journal of Biological Chemistry, vol. 265, No. 21, pp. 12127-12130 (1990).
Wen et al., “Erythropoietin Structure-Function Relationshops: High Degreee of Sequence Homology Among Mammals”, Blood, vol. 82, No. 5, pp. 1507-1516, (1993).
Roberts, MJ et al., “Chemistry for Peptide and ProteinPEGylation”, Advanced Drug Delivery Reviews, vol. 54, pp. 459-476 (2002).
Davidson Robert
Nett Juergen
Sethuraman Natarajan
GlycoFi, Incorporated
Heber Sheldon O.
Shafer Shulamith H.
Yablonsky Michael D.
LandOfFree
Erythropoietin compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Erythropoietin compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Erythropoietin compositions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4150766